Semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

A clinical trial funded by Novo Nordisk found that Ozempic (semaglutide) was linked with reduced pain among patients with ...

Researchers have discovered that semaglutide weight loss drugs like Ozempic may reduce the risk of early-onset colorectal cancer (CRC) in diabetes patients.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

In a groundbreaking new study, Ozempic was found to be so effective at treating arthritis that people no longer needed ...

Semaglutide was linked to a significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs.

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

In this week’s Bloom Boost – health news you might have missed, Gayle Guyardo , the host of the nationally syndicated health ...